公开(公告)号：US11279767B2

公开(公告)日：2022-03-22

申请号：US16115343

申请日：2018-08-28

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard Bourgon ,  David Fabrizio ,  Gregg Fine ,  Garrett M. Frampton ,  Priti Hegde ,  Sanjeev Mariathasan ,  Philip J. Stephens ,  James Xin Sun ,  Roman Yelensky

IPC: C07K16/28 ,  A61K39/395 ,  G16H20/10 ,  G16H50/30 ,  A61K39/00

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US11535671B2

公开(公告)日：2022-12-27

申请号：US16655495

申请日：2019-10-17

Applicant: Genentech, Inc.

Inventor： Priti Hegde ,  Marcin Kowanetz ,  Gregg Fine ,  Sanjeev Mariathasan ,  Richard Bourgon

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574 ,  A61K39/00

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.